Last reviewed · How we verify

DTPa-IPV/Hib vaccine

GlaxoSmithKline · Phase 3 active Biologic

DTPa-IPV/Hib vaccine is a Pentavalent inactivated vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameDTPa-IPV/Hib vaccine
SponsorGlaxoSmithKline
Drug classPentavalent inactivated vaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTPa-IPV/Hib is a pentavalent inactivated vaccine containing antigens from five pathogens. The acellular pertussis component (Pa) uses purified bacterial proteins rather than whole cells, reducing reactogenicity while maintaining immunogenicity. The vaccine primes both humoral and cell-mediated immune responses to protect against these five serious infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTPa-IPV/Hib vaccine

What is DTPa-IPV/Hib vaccine?

DTPa-IPV/Hib vaccine is a Pentavalent inactivated vaccine drug developed by GlaxoSmithKline, indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

How does DTPa-IPV/Hib vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is DTPa-IPV/Hib vaccine used for?

DTPa-IPV/Hib vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

Who makes DTPa-IPV/Hib vaccine?

DTPa-IPV/Hib vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is DTPa-IPV/Hib vaccine in?

DTPa-IPV/Hib vaccine belongs to the Pentavalent inactivated vaccine class. See all Pentavalent inactivated vaccine drugs at /class/pentavalent-inactivated-vaccine.

What development phase is DTPa-IPV/Hib vaccine in?

DTPa-IPV/Hib vaccine is in Phase 3.

What are the side effects of DTPa-IPV/Hib vaccine?

Common side effects of DTPa-IPV/Hib vaccine include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite, Vomiting.

Related